Table 4.
The clinical features of individual patients with CNS relapse
| Sex | Age | Histology | Stage | Site of involvement | IPI risk | First-line therapeutic regimen | Disease status at the presentation of CNS disease | Time to CNS event (months) | Pattern | Therapy directed to CNS disease | CNS response | Survival after CNS disease (months) |
| CNS involvement without systemic residual disease | ||||||||||||
| M | 44 | PTCL-NOS | IVB | Testis | HI | CHOP#6 | CR after CHOP | 32.13 | P/I | RT/ASCT | CR | 13.3 |
| M | 43 | PTCL-NOS | IIIB | Temporal bone | LI | CHOP#6 | CR after CHOP | 6.37 | P/I | RT | CR | 100.5 |
| M | 43 | PTCL-NOS | IVB | Nasal cavity, testis | LI | CHOP#3 | CR after ASCT | 9.00 | L/S | IT | PD | 1.0 |
| M | 56 | PTCL-NOS | IIIA | Infraauricular mass | LI | CHOP#6 | CR after ASCT | 29.60 | L/S | IT/CT | CR | 12.1+ |
| F | 24 | PTCL-NOS | IVA | Ovary, lung, thyroid | HI | CHOP#3 | CR after ASCT | 12.40 | L&P/S | RT | PR | 3.9 |
| F | 57 | EATL | IIIA | Colon | LI | CHOP#4 | CR after salvage therapy | 7.7 | L/S | CT | NE | 0.3 |
| M | 59 | ALCL, ALK− | IIB | Nasal cavity | L | CHOP#2 | CR after CHOP | 3.53 | P/S | Not done | NE | 2.8 |
| CNS involvement with systemic residual disease | ||||||||||||
| M | 55 | AITL | IVB | Omentum, liver, BM | HI | CHOP#2/IT | Initial diagnosis | 0 | L/S | IT/CT | CR | 4.6 |
| M | 54 | PTCL-NOS | IVA | Colon, ileum, BM | HI | CHOP#2/IT | Initial diagnosis | 0 | L/S | IT/CT | CR | 3.1 |
| F | 52 | AITL | IIIB | Peritoneal, inguinal LN | LI | CHOP#6 | PD after salvage CT | 71.23 | L/S | CT | NE | 2.7 |
| F | 69 | ALCL | IIB | Epiglottis | LI | CHOP#4 | PD after salvage CT | 5.73 | L/S | RT | PD | 0.07 |
| F | 50 | AITL | IIIA | Infraauricular mass | LI | CHOP#1 | During salvage CT | 2.90 | P/S | RT/IT/CT | PD | 3.6 |
| F | 59 | PTCL-NOS | IVB | BM, neck LN | LI | CHOP#1 | During salvage CT | 1.43 | P/S | RT/CT/ASCT | CR | 100.1 |
| M | 38 | ALCL, ALK+ | IVA | Small bowel, lung | LI | CHOP#3 | During salvage CT | 8.03 | L/S | IT/RT | CR | 2.5 |
| F | 57 | PTCL-NOS | IIIA | Stomach | LI | CHOP#5 | PD after salvage CT | 6.97 | L/S | RT | PD | 0.3 |
| F | 31 | ALCL, ALK+ | IVB | Skin, liver, BM | H | CHOP#2 | During first-line CT | 1.03 | L/S | Not done | NE | 0.2 |
| F | 59 | ALCL, ALK− | IVB | Nasopharynx, lung | HI | CHOP#1 | During first-line CT | 2.17 | L/S | IT | NE | 0.3 |
| M | 31 | PTCL-NOS | IVB | Skin, liver | H | CHOP#2 | During salvage CT | 1.90 | L/S | Not done | NE | 0.5 |
| M | 60 | PTCL-NOS | IVB | Jejunum, rib | H | Bortezomib-CHOP#1 | During first-line CT | 0.6 | L/S | IT/CT | CR | 6.7+ |
| F | 21 | PTCL-NOS | IVB | Skin, BM | LI | CHOP#3 | During first-line CT | 1.97 | L/S | IT/ASCT | CR | 4.6 |
PTCL-NOS, peripheral T-cell lymphoma, not otherwise specified; EATL, enteropathy-associated T-cell lymphoma; ALCL, anaplastic large cell lymphoma; ALK, anaplastic lymphoma; kinase; AITL, angioimmunoblastic T-cell lymphoma; IPI, international prognostic index; HI, high intermediate risk group; LI, low intermediate risk group; L, low risk group; H, high risk group; CHOP, combination chemotherapy with cyclophosphamide, doxorubicin, vincristine and prednisone; CR, complete remission; PR, partial remission; PD, progressive disease; NE, not evaluated; CT, chemotherapy; RT, whole-brain radiation therapy; IT, intrathecal chemotherapy; ASCT, autologous stem cell transplantation; P, parenchymal disease; L, leptomeningeal disease; I, isolated central nervous system (CNS) involvement; S, combined with systemic progression; BM, bone marrow; LN, lymph node.